Novavax Q1 Earnings Beat Expectations with Revenue Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy NVAX?
Source: seekingalpha
- Earnings Highlights: Novavax reported a Q1 GAAP EPS of -$0.06, beating expectations by $0.17, indicating some resilience in profitability despite significant revenue declines.
- Revenue Performance: The company generated $139.5 million in revenue for Q1, a 79.1% year-over-year decline, yet it exceeded market expectations by $58.51 million, suggesting ongoing competitive strength in the vaccine market.
- Expense Outlook: For the full year 2026, combined R&D and SG&A expenses are projected to be between $380 million and $420 million, with non-GAAP expenses expected to range from $310 million to $340 million, reflecting the company's focus on cost management.
- Market Reaction: Following the earnings release, Novavax shares rose by 6%, indicating investor confidence in the company's future prospects despite the challenges posed by declining revenues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVAX
Wall Street analysts forecast NVAX stock price to rise
6 Analyst Rating
3 Buy
0 Hold
3 Sell
Hold
Current: 9.230
Low
6.00
Averages
10.50
High
18.00
Current: 9.230
Low
6.00
Averages
10.50
High
18.00
About NVAX
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
Novavax Q1 Revenue Exceeds Expectations with Strong Vaccine Data
- Revenue Beat: Novavax reported Q1 revenue of $139.5 million, surpassing analysts' expectations of $78.3 million, primarily driven by licensing agreements and vaccine supply partnerships, indicating a strategic shift away from reliance on direct COVID vaccine sales.
- Increased Vaccine Preference: Data revealed that patients receiving Nuvaxovid were twice as likely to choose the same vaccine again next year compared to those who received Moderna's vaccine, providing Novavax with a significant competitive edge in the crowded vaccine market.
- 2026 Revenue Outlook: The company maintained its adjusted revenue forecast for 2026 at $230 million to $270 million, with expectations that existing cash and partner reimbursements will fund operations through 2028, even without additional milestone or royalty revenue.
- Optimistic Market Sentiment: Retail sentiment for NVAX on Stocktwits is deemed 'extremely bullish', with a 430% surge in message volume over 24 hours, reflecting strong investor confidence in the company's growth potential, despite a 4% downside from current price targets.
See More
Novavax (NVAX) Q3 2025 Earnings Transcript
See More
Novavax Q1 2026 Earnings Call Insights
- Strategic Partnerships: Novavax announced a non-exclusive licensing agreement with Pfizer to utilize Matrix-M technology in two infectious disease areas, with one already identified, indicating the company's strategic positioning in infectious disease treatment.
- Strong Financial Performance: In Q1 2026, Novavax reported total revenues of $140 million, with Nuvaxovid product sales of $10 million primarily driven by the German market, reflecting a significant shift as the company transitions its European operations to Sanofi.
- R&D Expense Guidance: The company reiterated its 2026 guidance for combined R&D and SG&A expenses between $310 million and $340 million, anticipating higher costs in the first half of 2026 but a significant decline in the second half, demonstrating a focus on cost management and future profitability.
- Healthy Cash Position: As of Q1 2026, Novavax reported $818 million in cash and accounts receivables, and despite a net loss of $9 million, the company maintains sufficient liquidity to support ongoing R&D and operations, ensuring continued business development.
See More
Novavax Reports Significant Q1 Revenue Growth
- Significant Revenue Growth: Novavax's licensing, royalties, and other revenue surged to $97 million in Q1, up from $45 million a year earlier, indicating strong performance in high-margin sectors and boosting investor confidence.
- Narrowed Net Loss: The company reported a net loss of $9 million in Q1, translating to a loss of $0.06 per share, which is significantly better than the $0.23 per share estimate, suggesting initial success in cost control efforts that may attract more investor interest.
- Deepening Strategic Partnerships: Novavax secured a $30 million upfront payment from Pfizer upon licensing its Matrix-M adjuvant, with potential for up to $500 million in development and sales milestones, highlighting the market value of its vaccine technology and future growth potential.
- Cost Control Initiatives: Under pressure from activist investors, Novavax plans to reduce combined research and administrative spending to $325 million by 2026 and $225 million by 2027, aiming to enhance profitability and strengthen its competitive position in the market.
See More
Novavax Exceeds Expectations in Q1 Financials, Shares Rise
- Strong Financial Performance: Novavax's Q1 results exceeded expectations, with a $30M boost from a licensing deal with Pfizer, leading to total revenues of $97.3M, reflecting a 116% year-over-year growth.
- Decline in Vaccine Sales: Despite total revenues of $139.5M, down 79% year-over-year, the figure surpassed consensus estimates by $58.5M, primarily due to a significant drop in sales of the Nuvaxovid vaccine.
- Net Loss Reported: The company reported a net loss of $9.5M in Q1, a stark contrast to a net income of $518.6M in the same quarter last year, highlighting the impact of weak sales.
- Cost Reduction Initiatives: Novavax reiterated its full-year revenue guidance while increasing its expense reduction target for 2028 to over $500M, indicating progress in its ongoing cost-cutting efforts.
See More
Trump Promises Full Report on Hantavirus Outbreak
- Outbreak Overview: The hantavirus outbreak aboard the Dutch-flagged cruise ship Hondius has resulted in three deaths and six confirmed infections among 150 passengers, prompting global attention, with Trump promising a detailed report on Friday, indicating the government's seriousness about the situation.
- Vaccine Development Update: Moderna's partnership with Korea University to develop an mRNA hantavirus vaccine has gained attention, receiving a $176 million government award in 2024, highlighting its critical role in pandemic response and potential to accelerate vaccine development timelines.
- Market Reaction: Vaccine manufacturers and biodefense companies saw stock rallies on Friday night, with Emergent BioSolutions up 3%, Inovio and Novavax each gaining 2%, and Moderna rising 1%, reflecting investor optimism regarding vaccine development amid the outbreak.
- Investor Sentiment: On Stocktwits, retail sentiment for Inovio and Novavax was extremely bullish, while Moderna showed positive sentiment, indicating high market interest in hantavirus-related companies, with Moderna's stock surging 102% over the past year.
See More
Novavax Q1 Revenue Exceeds Expectations with Strong Vaccine Data
- Revenue Beat: Novavax reported Q1 revenue of $139.5 million, surpassing analysts' expectations of $78.3 million, primarily driven by licensing agreements and vaccine supply partnerships, indicating a strategic shift away from reliance on direct COVID vaccine sales.
- Increased Vaccine Preference: Data revealed that patients receiving Nuvaxovid were twice as likely to choose the same vaccine again next year compared to those who received Moderna's vaccine, providing Novavax with a significant competitive edge in the crowded vaccine market.
- 2026 Revenue Outlook: The company maintained its adjusted revenue forecast for 2026 at $230 million to $270 million, with expectations that existing cash and partner reimbursements will fund operations through 2028, even without additional milestone or royalty revenue.
- Optimistic Market Sentiment: Retail sentiment for NVAX on Stocktwits is deemed 'extremely bullish', with a 430% surge in message volume over 24 hours, reflecting strong investor confidence in the company's growth potential, despite a 4% downside from current price targets.
See More
Novavax (NVAX) Q3 2025 Earnings Transcript
See More
Novavax Q1 2026 Earnings Call Insights
- Strategic Partnerships: Novavax announced a non-exclusive licensing agreement with Pfizer to utilize Matrix-M technology in two infectious disease areas, with one already identified, indicating the company's strategic positioning in infectious disease treatment.
- Strong Financial Performance: In Q1 2026, Novavax reported total revenues of $140 million, with Nuvaxovid product sales of $10 million primarily driven by the German market, reflecting a significant shift as the company transitions its European operations to Sanofi.
- R&D Expense Guidance: The company reiterated its 2026 guidance for combined R&D and SG&A expenses between $310 million and $340 million, anticipating higher costs in the first half of 2026 but a significant decline in the second half, demonstrating a focus on cost management and future profitability.
- Healthy Cash Position: As of Q1 2026, Novavax reported $818 million in cash and accounts receivables, and despite a net loss of $9 million, the company maintains sufficient liquidity to support ongoing R&D and operations, ensuring continued business development.
See More
Novavax Reports Significant Q1 Revenue Growth
- Significant Revenue Growth: Novavax's licensing, royalties, and other revenue surged to $97 million in Q1, up from $45 million a year earlier, indicating strong performance in high-margin sectors and boosting investor confidence.
- Narrowed Net Loss: The company reported a net loss of $9 million in Q1, translating to a loss of $0.06 per share, which is significantly better than the $0.23 per share estimate, suggesting initial success in cost control efforts that may attract more investor interest.
- Deepening Strategic Partnerships: Novavax secured a $30 million upfront payment from Pfizer upon licensing its Matrix-M adjuvant, with potential for up to $500 million in development and sales milestones, highlighting the market value of its vaccine technology and future growth potential.
- Cost Control Initiatives: Under pressure from activist investors, Novavax plans to reduce combined research and administrative spending to $325 million by 2026 and $225 million by 2027, aiming to enhance profitability and strengthen its competitive position in the market.
See More
Novavax Exceeds Expectations in Q1 Financials, Shares Rise
- Strong Financial Performance: Novavax's Q1 results exceeded expectations, with a $30M boost from a licensing deal with Pfizer, leading to total revenues of $97.3M, reflecting a 116% year-over-year growth.
- Decline in Vaccine Sales: Despite total revenues of $139.5M, down 79% year-over-year, the figure surpassed consensus estimates by $58.5M, primarily due to a significant drop in sales of the Nuvaxovid vaccine.
- Net Loss Reported: The company reported a net loss of $9.5M in Q1, a stark contrast to a net income of $518.6M in the same quarter last year, highlighting the impact of weak sales.
- Cost Reduction Initiatives: Novavax reiterated its full-year revenue guidance while increasing its expense reduction target for 2028 to over $500M, indicating progress in its ongoing cost-cutting efforts.
See More
